Document is current
Any future updates will be listed below
-
Authors
Aoki, Tomoko https://orcid.org/0000-0002-9950-4553
Kudo, Masatoshi https://orcid.org/0000-0002-4102-3474
Nishida, Naoshi https://orcid.org/0000-0002-9111-5668
Ueshima, Kazuomi https://orcid.org/0000-0002-7577-5789
Tsuchiya, Kaoru
Tada, Toshifumi https://orcid.org/0000-0002-0976-6761
Morita, Masahiro
Chishina, Hirokazu
Takita, Masahiro
Hagiwara, Satoru
Ida, Hiroshi
Minami, Yasunori https://orcid.org/0000-0001-7146-5954
Kuroda, Hidekatsu https://orcid.org/0000-0002-1471-1087
Nakamura, Noriaki
Hiraoka, Atsushi https://orcid.org/0000-0003-1989-0480
Tomonari, Tetsu https://orcid.org/0000-0002-8484-9866
Tani, Joji
Naganuma, Atsushi https://orcid.org/0000-0003-0663-0102
Kakizaki, Satoru https://orcid.org/0000-0003-0224-7093
Ogawa, Chikara https://orcid.org/0000-0002-4534-6692
Hatanaka, Takeshi https://orcid.org/0000-0003-3656-285X
Ishikawa, Toru https://orcid.org/0000-0002-5470-9694
Kawata, Kazuhito https://orcid.org/0000-0002-4986-8578
Takebe, Atsushi
Matsumoto, Ippei https://orcid.org/0000-0003-3965-3693
Hidaka, Masaaki
Kurosaki, Masayuki https://orcid.org/0000-0001-7016-8931
Kumada, Takashi https://orcid.org/0000-0003-2211-495X
Izumi, Namiki https://orcid.org/0000-0002-0055-8229
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (24K10393, 21K07184)
- License Information
-
More Information
Article History
Received: 29 September 2024
Accepted: 18 February 2025
First Online: 7 March 2025
Declarations
:
: T.A. received lecture fees; Eisai. M.K. received grants from Taiho Pharmaceuticals, Chugai Pharmaceuticals, Otsuka, Takeda, GE Healthcare, AbbVie, Astellas Pharma, Eisai, Eli Lilly, and AstraZeneca. He has also received grants and personal fees from Eisai, Roche, Chugai, and AstraZeneca. N.N. No relevant conflicts of interest to disclose. K.U. received honoraria from Eisai, Takeda and Chugai. K.T. received lecture fees; Chugai, Eisai, AstraZeneca, Takeda. T.T.: received lecture fees; Abbvie, Chugai and Eisai. M.M. No relevant conflicts of interest to disclose. H.C. No relevant conflicts of interest to disclose. M.T. No relevant conflicts of interest to disclose. S.H. No relevant conflicts of interest to disclose. H.I. No relevant conflicts of interest to disclose. Y.M. No relevant conflicts of interest to disclose. H.K. No relevant conflicts of interest to disclose. N.N. No relevant conflicts of interest to disclose. A.H.: received lecture fees; Chugai, AstraZeneca and Eli Lilly. T.T. No relevant conflicts of interest to disclose. J.T. received lecture fees; AstraZeneca. A.N. No relevant conflicts of interest to disclose. S.K.: received lecture fees; Abbvie. C.O. received lecture fees; Chugai. T.H. received lecture fees; Eisai. T.I. No relevant conflicts of interest to disclose. K.K. No relevant conflicts of interest to disclose. A.T. No relevant conflicts of interest to disclose. I.M. No relevant conflicts of interest to disclose. M.H. No relevant conflicts of interest to disclose. M.K. received lecture fees; Eisai, Bayer, Lilly, Chugai, Takeda, AstraZeneca. T.K.: received lecture fees; Eisai. N.I. received lecture fees; Chugai, AstraZeneca, Eisai, Takeda.
: This study was approved by the Medical Ethics Committee of Kindai University Hospital (Approval R02-258) in 2020, and written informed consent was obtained from all patients.
